Sovaldi (sofosbuvir) costs $84,000 per course of treatment in the country, a price that the Southeastern Pennsylvania Transportation Authority (SEPTA) claims is ‘exorbitant’ and in “sharp contrast to the prices at which Sovaldi is being made available by Gilead in other countries”.
Its suit points to Gilead’s licensing of the pill to generic companies in developing countries at a ‘deeply discounted’ price and its estimated $900 cost in Egypt as examples of this ‘obvious paradox’.
“Gilead is not authorized by the patent laws (or otherwise) to abuse its purported monopoly on Sovaldi by charging discriminatory prices that apparently have no rational basis other than to inflate the company’s bottom line,” the company adds.
“Gilead’s price gouging has had at least two detrimental consequences in this country. It has, obviously, resulted in the consumers and entities that have purchased Sovaldi paying significant prices for the drug. It has also effectively priced some consumers and government programs alike out of the Sovaldi market, thereby preventing needed recipients from obtaining this critical drug. (Más)